UNICREDIT BANK/CALL/NOVO-NORDISK B/1400/0.1/18.06.25 | Market Closed - BOERSE MUENCHEN 01:15:04 12/06/2024 am IST | ||
| 0.55 EUR | -5.17% |
|
| Current month | +25.00% | ||
| 1 month | +34.15% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 11/24/11 | 0.55 | -5.17% |
| 10/24/10 | 0.58 | +1.75% |
| 07/24/07 | 0.57 | +5.56% |
| 06/24/06 | 0.54 | +3.85% |
| 05/24/05 | 0.52 | +13.04% |
Real-time BOERSE MUENCHEN
Last update June 12, 2024 at 01:15 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
UniCredit
|
| WKN | HD31CL |
| ISIN | DE000HD31CL2 |
| Date issued | 26/02/2024 |
| Strike | 1,400 kr |
| Maturity | 18/06/2025 (372 Days) |
| Parity | 10 : 1 |
| Emission price | 0.35 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.78 € |
|---|---|
| Lowest since issue | 0.3 € |
| Spread | 0.04 € |
| Spread % | 7.02% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
982
DKK
Average target price
929.5
DKK
Spread / Average Target
-5.35%
- Stock Market
- Warrants
- Warrant
